Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.56 |
| ▸ | CASP3 | P42574 | 1/20 | 0.53 |
| ▸ | GRM5 | P41594 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | BRD4 | O60885 | 1/20 | 0.50 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.48 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.48 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.48 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.48 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.46 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.46 |
| ▸ | TNF | P01375 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4379040 | 1.00 | KMT2A (0.56) | KMT2ACASP3GRM5NPSR1BRD4 | |
| SCHEMBL10927175 | 0.94 | KMT2A (0.51) | KMT2ACASP3GRM5NPSR1BRD4 | |
| SCHEMBL10926803 | 0.90 | ADRA1D (0.55) | KMT2ACASP3GRM5NPSR1BRD4 | |
| SCHEMBL10927835 | 0.88 | KMT2A (0.48) | KMT2ACASP3GRM5NPSR1BRD4 | |
| SCHEMBL10927830 | 0.88 | KMT2A (0.48) | KMT2ACASP3GRM5NPSR1BRD4 | |
| SCHEMBL16862983 | 0.86 | KDM4E (0.66) | KMT2AGRM5NPSR1BRD4ADRA1D | |
| SCHEMBL21997738 | 0.85 | CASP3 (0.55) | KMT2ACASP3GRM5BRD4ADRA1D | |
| SCHEMBL10925461 | 0.84 | ADRA1D (0.58) | KMT2ACASP3NPSR1ADRA1DADRA1A | |
| SCHEMBL18954624 | 0.84 | ALDH1A1 (0.64) | BRD4PKMTSHRALDH1A1MAPT | |
| SCHEMBL2258501 | 0.83 | KMT2A (0.70) | KMT2ACASP3NPSR1PKMTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260062407-A1 | PEROXIREDOXIN 3 INHIBITORS AND METHODS OF USE FOR TREATING CANCER | UNIV WAKE FOREST HEALTH SCIENCES (US) | 2026-03-05 | — | — | US | disclosed |
| WO-2025260150-A1 | NOVEL N-BENZYL PHTHALIMIDES FOR THE TREATMENT OF PAIN. METHODS OF PREPARATION AND THERAPEUTIC USE | MICROBIOLÓGICA QUÍMICA E FARMACÊUTICA LTDA. (BR) | 2025-12-26 | — | — | WO | disclosed |
| US-20250381278-A1 | PEROXIREDOXIN 3 INHIBITORS AND METHODS OF USE FOR TREATING CANCER | UNIV WAKE FOREST HEALTH SCIENCES (US) | 2025-12-18 | — | — | US | disclosed |
| US-20250011316-A1 | PEROXIREDOXIN 3 INHIBITORS AND METHODS OF USE FOR TREATING CANCER | WAKE FOREST UNIVERSITY HEALTH SCIENCES | 2025-01-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260062407-A1 | PEROXIREDOXIN 3 INHIBITORS AND METHODS OF USE FOR TREATING CANCER | PRDX1, PRDX3, PRDX2 | KMT2A 4417/4885CASP3 74/4885GRM5 2890/4885 |
| US-20250011316-A1 | PEROXIREDOXIN 3 INHIBITORS AND METHODS OF USE FOR TREATING CANCER | PRDX1, PRDX2, PRDX6 | KMT2A 2870/4885CASP3 87/4885GRM5 1992/4885 |
| US-20250381278-A1 | PEROXIREDOXIN 3 INHIBITORS AND METHODS OF USE FOR TREATING CANCER | PRDX1, PRDX2, PRDX6 | KMT2A 2813/4885CASP3 85/4885GRM5 2127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.